MACK Stock Overview: Comprehensive Insights on Merrimack Pharmaceuticals, Inc. Shares

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

Altman Z Score 4.98
Piotroski Score 2.00
Grade Neutral

Company brief: Merrimack Pharmaceuticals, Inc. (MACK)

Sector Healthcare
Industry Biotechnology
CEO Mr. Gary L. Crocker M.B.A.
Website https://www.merrimack.com
Country US
Employees (FY) N/A
Founded 03/29/2012
ISIN US5903282094

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Company Calendar

Last Earnings N/A
Ex-Dividend for 5/16 Dividend 05/20/2024
Dividend Payable N/A
Today N/A
Next Earnings (Estimated) 08/01/2024
Fiscal Year End N/A

Price Target and Rating

Average Stock Price Target $0.00
High Stock Price Target $0.00
Low Stock Price Target $0.00
Potential Upside/Downside N/A
Consensus Rating Sell
Rating Score (0-4) N/A
Research Coverage N/A

Profitability

EPS (Most Recent Fiscal Year) -$0.09
Trailing P/E Ratio -168.11
Forward P/E Ratio -168.11
P/E Growth -168.11
Net Income $-1,181,000

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Latest News of MACK

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

By businesswire.com | 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) announced that the stockholders at a Special Meeting held today overwhelmingly ...
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

By businesswire.com | 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has filed notice with NASDAQ of the Company's intent to...
Merrimack Receives $225 Million Milestone Payment from Ipsen

By businesswire.com | 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has received a $225 million payment which was due from ...
Merrimack Reports Full Year 2023 Financial Results

By businesswire.com | 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2023 Financial Results....
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

By businesswire.com | 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) reported that Ipsen, SA (“Ipsen”) issued a press release today announcing t...
Merrimack Reports Third Quarter 2023 Financial Results

By businesswire.com | 8 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Third Quarter 2023 Financial Results....
Merrimack Reports Second Quarter 2023 Financial Results

By businesswire.com | 11 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2023 Financial Results....
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments

By businesswire.com | 1 year ago

BERWYN, Pa.--(BUSINESS WIRE)--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-t...
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar

By businesswire.com | 1 year ago

BERWYN, Pa.--(BUSINESS WIRE)--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-t...